Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 32Thoracic 9Gastrointestinal 9Tumor-Agnostic 6Other solid neoplasm 4Gynecologic 3Head & Neck 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 2Carcinoma 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Axitinib × Head & Neck × Clear all
NCT00389441 2013-11-25

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Pfizer

Phase 2 Completed
52 enrolled 9 charts
Head & Neck

Carcinoma, Thyroid Neoplasms

NCT00094055 2012-06-26

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Pfizer

Phase 2 Completed
60 enrolled 9 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡